Editorials

Can the Events of Early Life Influence the Development of Rheumatoid Arthritis? C.J. Edwards ................................................. 1

On Anti-Tumor Necrosis Factor-induced Systemic Lupus Erythematosus N. Jacob, C.O. Jacob ................................. 3

A Novel Composite Endpoint to Evaluate the Gastrointestinal Effects of NSAID Through the Entire GI Tract: Introducing CSULGIE C.J. Hawkey ......................... 6

Review


Articles

Increased Levels of IL-33 in Sera and Synovial Fluid from Patients with Active RA Y. Matsuyama, H. Okazaki, H. Tamemoto, et al. .......... 18


Clinical Features and Prognosis of Late-onset SLE: Results from the 1000 Faces of Lupus Study S. Lalani, J. Pope, F. de Leon, C. Peschken, and the Members of CaNiOS/1000 Faces of Lupus .......... 38


Fyn and CD70 Expression in CD4+ T Cells from Patients with SLE A. Kozłowska, P. Hrycaj, J.K. Lacki, P.P. Jagodzinski .......... 53

IL-6 Deficiency Delays Lupus Nephritis in MRL-Fas™ Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in SLE H. Cash, M. Relle, J. Menke, et al. ...................... 60


Myocardial Left Ventricular Dysfunction in Patients with SLE: New Insights from Tissue Doppler and Strain Imaging S.J. Buss, D. Wolf, G. Korosoglou, et al. ...................... 79

The Use of Micronutrient Supplements is Not Associated with Better Quality of Life and Disease Activity in Canadian Patients with SLE E. Aghdasii, S. Morrison, C. Landolt-Marticorena, et al. ...................... 87

Serum Concentrations of IL-1β, CXCL10, and IFN-γ in Mixed Cryoglobulinemia Associated with Hepatitis C Infection A. Antonelli, C. Ferri, S.M. Ferrari, et al. ...................... 91

Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension A.A. Shah, F.M. Wigley, L.K. Hummers ................................. 98

Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group O. Kowal-Bielecka, J. Avouac, D. Pittrow, et al, for the EPOSS Group .................................................. 105

Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis A.L. Herrick, M. Lunt, N. Whidby, et al. ...................... 116


Baseline Glucocorticoid Dose and BMD Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis J-P. Devogelaer, R.A. Adler, C. Recknor, et al. ...................... 141


Demographic and Clinical Features Related to a Symptomatic Onset of Paget’s Disease of Bone M. Varenna, F. Zucchi, L. Galli, M. Manara, G. de Marco, L. Singaglia ................................. 155

Contents continued on page lviii
Signs of Accelerated Preclinical Atherosclerosis in Patients with AS
M.J.L. Peters, I.C. van Eijk, Y.M. Smulders, et al. .......................... 161
A Novel Composite Endpoint to Evaluate the GI Effects of NSAID Through the Entire GI Tract

Pediatric Rheumatology
Treatment of Pediatric Localized Scleroderma: Results of a Survey of North American Pediatric Rheumatologists
Unresponsiveness to Colchicine Therapy in Patients with Familial Mediterranean Fever Homozygous for the M694V Mutation
O. Soylemezoglu, M. Arga, K. Fidan, et al. .................. 182

Images in Rheumatology
Transfusion-related Acute Lung Injury During IVIG Treatment
P.V. Voulgari, S. Paschou, E. Svama, N. Tsifetaki, A.A. Drosos .................. 190
Heel Enthesopathy of DISH Resembling Enthesitis of SpA
I. Olivieri, S. D’Angelo, F. Borraccia, A. Padula ..................... 192
Severe Adult-Onset Calcinosis in a Patient with a History of Juvenile DM
P. Efthimiou, M. Kukar, L.J. Kagen ...................... 194

Historical Vignette
Philip Hench, a Nobel Link in the Evolution of The Canada Gairdner International Awards
D.A. Gordon, T. Anastassiades .......................... 195

Tribute
Sonia Gruson, Managing Editor 1978-1994
D. Lagana, C. Rodrigo, J. Meyers, et al. ................. 199

Correspondence
Risk Factors for Cardiovascular Disease in RA: Defining Treatment Thresholds
V. Ravindran, R.A. Hughes .......................... 200

Letters
Induction of SLE with Tumor Necrosis Factor Blockers
E. Soforo, M. Baumgartner, L. Francis, F. Allam, P.E. Phillips, A. Perl .................. 204
HLA-DRB1 Alleles and RA-related Pulmonary Fibrosis
K. Migita, T. Nakamura, T. Koga, K. Eguchi .................. 205
Low Level (Below Cutoff) of Anti-CCP Test Results in Diagnosis of RA in a High-risk Population
D-A. Kim, T-Y. Kim .......................... 208
Recommended Screening Strategy for Preventing TB Flare in Patients with Inflammatory Rheumatic Diseases Receiving TNF-α Inhibitors in India — Followup Report
A.N. Malaviya, S. Kapoor, S. Garg, R. Rawat .................. 209
Successful Use of Etanercept in Acquired Angioedema in a Patient with Ps
M. Rottem, R. Mader ..................... 209
Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with RA During Treatment with Etanercept
S. Takatori, Y. Kamata, T. Murosaki, M. Iwamoto, S. Minota .......................... 210
Inflammatory Arthritis in a Patient with Primary Biliary Cirrhosis: B Cell Mediated Synovitis
ANCA-positive Digital Necrosis in a Patient with Limited SSC
M. Wong, V.K. Ranganath, P.J. Clements .......................... 214

Correction
Reactivation of Hepatitis B Viral Infection in Inactive HBsAg Carriers Following Anti-Tumor Necrosis Factor-α Therapy
S-J. Chung, J.K. Kim, M-C. Park, Y-B. Park, S-K. Lee .... 216

Meetings in Rheumatology .......................... xi